AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the ...

Enhanced Income Fund outperformed the benchmark over the fourth quarter of 2025 on a gross and net basis. Read more here.

MSAD 51 education support professionals have been working without a contract since July 1 and attended the March 5 board meeting demanding change.

The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience. The ...

After-tax NPV(8%) of $473M (US$346.6M) and 2.2-year payback from start of production with IRR of 48.8% at US$1,000/mtu WO3 Key Highlights: All amounts in Canadian dollars unless stated ...